Last reviewed · How we verify

NCT05386199: SERO-22

The Role of Serotonin in Intensive Care Patients

Status unknown Last updated 31 May 2022
What this trial tests

trial in Sepsis in 250 participants. Status unknown.

Timeline
25 May 2022
Primary endpoint
31 December 2024
31 December 2024

Quick facts

Lead sponsorOslo University Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment250
Start date25 May 2022
Primary completion31 December 2024
Estimated completion31 December 2024
Sites1 location across Norway

Conditions studied

Sponsor

Oslo University Hospital

Who can join

18 and older, any sex, with Sepsis or Septic Shock. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Sepsis, cardiac arrest and multiple trauma are potentially life-threatening conditions and common reasons for intensive care unit (ICU) admission. The aim of this study is to investigate the role of the signaling substance serotonin in blood in these conditions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Sepsis

Currently open trials in the same condition.

Other Oslo University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05386199.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing